Monthly Archives: June 2010

Colors of a Dream at Tulum Ruins Beach on Mexico’s Riviera Maya

Posted on by

Have you ever dreamed in Technicolor and woken up thinking that those colors simply don’t exist in real life? Those rich, saturated, almost kaleidoscopic colors are what I experienced when I visited the beach at the Mayan ruins in Tulum, Mexico.

Turquoise water and pure white sand, set against a jagged rock cliffside

But wait. I’m getting ahead of myself. To get to the beach I had to pass through the ruins which are quite spectacular for their oceanfront location. During the height of the Maya empire this was an important port city and the major structures face the ocean from a high mound: a watchtower and astronomical observatory are stunning examples of the ancient architecture, as is a house built over a cenote. Once you’ve had your fill of wandering through the ruins, a wooden staircase leads down the cliff to the beach, an exquisite cove of pure white, sugar-fine sand bordered on both ends by ochre and red rock outcroppings. Gentle waves sweep into the sheltered cove, beckoning bathers into a sea so dazzlingly turquoise and aquamarine that it hurts the eyes.

Stairway leads down the cliff from the ancient ruins of Tulum to a stunning beach

Those who don’t care to swim can soak up the rays or clamber around the giant boulders and pinnacles on either end of the beach to discover more secluded pockets where crystal seas lap through holes in the rock. The beach has a year-round lifeguard, but it is only open until 5 p.m. each day, when the archeological park closes. Price of admission is 51 pesos (about $4.50 USD) and includes complete access to the ruins and the beach.

Photo Credit: Barbara Weibel
Article by Barbara Weibel of Hole In The Donut Travels

Lost Language Department – Up The Stairs

Posted on by

post thumbnail

Gonaives Haiti
Gonaives Haiti, Photo by Michael Johnson

It’s been sort of a rough week for my head. It seems as though I’m not only losing my English but simultaneously sucking at Spanish. I guess the English started slipping over time and with such immersion, it’s only a matter of time before the grammar starts to go. According to my dad, my blogs are getting sloppier and sloppier. I now speak no language well.

It’s been sort of a rough week for my head. It seems as though I’m not only losing my English but simultaneously sucking at Spanish.

Canada flag
Canada flag, Photo by Sam Daams

Last week when I spent the afternoon at an estancia with my job, assisting Canadian tourists, I could see how my English was exaggerated and forced. It seemed like I was subconsciously speaking with a slight Spanish accent. But why? I guess because the majority of the time that I hear English (not counting TV), it comes from a second language speaker. So over time, I’ve forgotten what English should actually sound like and naturally correct myself when a mistake is made. Basically, I spend all day in a Spanish speaking environment and either come home and continue in Spanish or don’t speak to anyone else.

This is disconcerting to me because obviously I don’t want to lose my linguistic skills in my own tongue that I spent years developing, but at the same time don’t want to sacrifice my Spanish skills and give it all up. But for now, despite my best efforts, I sound like an idiot in Spanish, which brings us to the second point of tonight’s topic. I guess since Monday I’ve noticed that my Spanish has taken a nose dive this week. I’m not that surprised by it because once every few months my brain just has a meltdown and I can’t talk for about a week. It’s part of the learning process.

The funny thing is I was describing this process to a co-worker on Monday and realized that I couldn’t roll my r’s quickly and the pronunciation was just terrible for my standards.

The funny thing is I was describing this process to a co-worker on Monday and realized that I couldn’t roll my r’s quickly and the pronunciation was just terrible for my standards.

Rolling Rs

This is how I realized I’ve hit the dry spell. It’s like my mouth has gotten lazy. I’m also having trouble understanding Spanish. This morning when trying to say ‘pero’ (but) I said ‘Perú.’ Maybe reading a book in Spanish is a reason—just overloading my head and causing a reboot. Hopefully by the end of the week or early next week I’ll be back to where I was. Or I need to rest and regroup.

bike ride
bike ride, Photo by Peacocks

This struggle just reiterates to me that it’s extremely difficult to become truly fluent in another language. I mean 100% to the point that people have no idea you are from a different country. I’ve met these people before, and when they spoke English I couldn’t tell they were from another country with a different language. It takes years and influence as a child, as well as dedication on their part. I don’t know if I will reach that stage in the limited time I’ve had to study and live with Spanish.

I’ve discussed with friends in the past the difficulties we have with developing a second language. We have agreed that sometimes to be excellent in another language you need to sacrifice some of your natural skills. Otherwise, you get too confused. There are times when I purposely make mistakes as a joke, but other times when a mistake in English comes out, I take a step back in shock. “Wow, that just happened.”

For the time being, I need to ride out this stretch of lousy Spanish and keep improving. As for the English, it’s just a matter of time until that bounces back, but before I move home to the States I wonder how much worse it could get. I can’t imagine the embarrassment of showing up for grad school on the first day and saying, ‘Hi, I’m Jon, I have 25 years.’

© Gretchen for TravelBlogs, 2010. |
Lost Language Department – Up The Stairs |
No comment |

Post categories: Articles
Post tags: , , , , , ,

International Stem Cell Corporation’s Parthenogenetic Stem Cell Patent is Approved by the United States Patent and Trademark Office

Posted on by

International Stem Cell Corporation (OTCBB:ISCO), http://www.intlstemcell.com, announced today that the United States Patent and Trademark Office (USPTO) has granted ISCO patent number 7,732,202, the first of several pending patents relating to its development of human parthenogenetic Stem Cells (hpSC). Human parthenogenetic stem cells are a new type of pluripotent stem cell that allows immune matching to potentially solve critical immune rejection problems, and does not involve the ethical issues that surround the use of fertilized human embryos.

Although ISCO's creation of human parthenogenetic stem cells was first announced in a peer review publication in 2007, the formal allowance of claims by the USPTO will greatly advance the field of regenerative medicine by allowing ISCO to share its knowledge of these hpSC lines more freely with researchers in the US and around the world through partnerships, joint ventures, funded research and licensing arrangements.

The patent protects ISCO's technology platform, allowing the creation of hpSC from unfertilized eggs, exhibiting similar qualities and pluripotency as embryonic stem cells, with the added ability to be immune-matched to the donor, as illustrated in published peer-reviewed articles. Additional discoveries, also previously published in a peer reviewed journal and the subject of pending ISCO patents, illustrate the creation of 'homozygous' hpSC that can be immune matched to millions of persons of differing sexes and racial backgrounds, rather than only to the donor or her family, raising the potential of eventually creating a universal source of stem cells that could benefit most the of the world's population.

Researchers across the world work with ISCO to study different therapeutic applications of hpSC. Through previously announced collaborative arrangements, ISCO's scientists are working with major universities and private research organizations to study hpSC to treat liver disease, diabetes, Age-related Macular Degeneration (AMD), corneal blindness and various neural degenerative diseases. In one such research collaboration, internationally-recognized stem cell researcher Hans Keirstead, PhD, at the Reeve-Irvine Research Center (University of California, Irvine), recently published a paper, referring to his use of embryonic stem cells and ISCO's hpSC in work focused on the derivation of early retinal progenitor tissue.

Andrey Semechkin, PhD, CEO of ISCO said, 'Other than parthenogenetic stem cells, the three most commonly used and described types of stem cells are human embryonic stem cells (hESC), induced pluripotent stem cells (iPS), and adult stem cells, such as those derived from cord blood, adipose tissue or bone marrow. Parthenogenetic stem cells have unique advantages over each of these other cell types, and we anticipate that since our core patent has been issued, we can now accelerate the adoption of our hpSC lines by researchers in the US and throughout the world.'

'International Stem Cell Corporation is particularly proud of these accomplishments because we have been funded thus far entirely by investors, without NIH or other governmental aid,' said Jeffrey Janus, Senior Vice President of ISCO. 'However, once it is generally recognized that parthenogenetic cells have similar characteristics of embryonic stem cells and offer the potential to solve critical immune rejection issues - while not requiring the destruction of viable human embryos - we expect these cells to be increasingly used in government funded research to study ways of reducing human suffering and treating intractable human diseases.'

ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB):

International Stem Cell Corporation is a California-based biotechnology company focused on therapeutic and research products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing sexes, ages and racial groups. This offers the potential to create the first true stem cell bank, UniStemCell(TM), while avoiding the ethical issue of using fertilized eggs. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology. More information is available at ISCO's website, http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

FORWARD-LOOKING STATEMENTS

Statements pertaining to anticipated technological developments and therapeutic applications, and other opportunities for the company and its subsidiary, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," " anticipates," "expects," "estimates,") should also be considered to be forward- looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.

Key Words: Stem Cells, Biotechnology, Parthenogenesis

International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com
or
Brian Lundstrom, President
760-640-6383
bl@intlstemcell.com

International Stem Cell Corporation's Parthenogenetic Stem Cell Patent is Approved by the United States Patent and Trademark Office

Posted on by

International Stem Cell Corporation (OTCBB:ISCO), http://www.intlstemcell.com, announced today that the United States Patent and Trademark Office (USPTO) has granted ISCO patent number 7,732,202, the first of several pending patents relating to its development of human parthenogenetic Stem Cells (hpSC). Human parthenogenetic stem cells are a new type of pluripotent stem cell that allows immune matching to potentially solve critical immune rejection problems, and does not involve the ethical issues that surround the use of fertilized human embryos.

Although ISCO's creation of human parthenogenetic stem cells was first announced in a peer review publication in 2007, the formal allowance of claims by the USPTO will greatly advance the field of regenerative medicine by allowing ISCO to share its knowledge of these hpSC lines more freely with researchers in the US and around the world through partnerships, joint ventures, funded research and licensing arrangements.

The patent protects ISCO's technology platform, allowing the creation of hpSC from unfertilized eggs, exhibiting similar qualities and pluripotency as embryonic stem cells, with the added ability to be immune-matched to the donor, as illustrated in published peer-reviewed articles. Additional discoveries, also previously published in a peer reviewed journal and the subject of pending ISCO patents, illustrate the creation of 'homozygous' hpSC that can be immune matched to millions of persons of differing sexes and racial backgrounds, rather than only to the donor or her family, raising the potential of eventually creating a universal source of stem cells that could benefit most the of the world's population.

Researchers across the world work with ISCO to study different therapeutic applications of hpSC. Through previously announced collaborative arrangements, ISCO's scientists are working with major universities and private research organizations to study hpSC to treat liver disease, diabetes, Age-related Macular Degeneration (AMD), corneal blindness and various neural degenerative diseases. In one such research collaboration, internationally-recognized stem cell researcher Hans Keirstead, PhD, at the Reeve-Irvine Research Center (University of California, Irvine), recently published a paper, referring to his use of embryonic stem cells and ISCO's hpSC in work focused on the derivation of early retinal progenitor tissue.

Andrey Semechkin, PhD, CEO of ISCO said, 'Other than parthenogenetic stem cells, the three most commonly used and described types of stem cells are human embryonic stem cells (hESC), induced pluripotent stem cells (iPS), and adult stem cells, such as those derived from cord blood, adipose tissue or bone marrow. Parthenogenetic stem cells have unique advantages over each of these other cell types, and we anticipate that since our core patent has been issued, we can now accelerate the adoption of our hpSC lines by researchers in the US and throughout the world.'

'International Stem Cell Corporation is particularly proud of these accomplishments because we have been funded thus far entirely by investors, without NIH or other governmental aid,' said Jeffrey Janus, Senior Vice President of ISCO. 'However, once it is generally recognized that parthenogenetic cells have similar characteristics of embryonic stem cells and offer the potential to solve critical immune rejection issues - while not requiring the destruction of viable human embryos - we expect these cells to be increasingly used in government funded research to study ways of reducing human suffering and treating intractable human diseases.'

ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB):

International Stem Cell Corporation is a California-based biotechnology company focused on therapeutic and research products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing sexes, ages and racial groups. This offers the potential to create the first true stem cell bank, UniStemCell(TM), while avoiding the ethical issue of using fertilized eggs. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology. More information is available at ISCO's website, http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

FORWARD-LOOKING STATEMENTS

Statements pertaining to anticipated technological developments and therapeutic applications, and other opportunities for the company and its subsidiary, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," " anticipates," "expects," "estimates,") should also be considered to be forward- looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to updat
e these forward-looking statements.

Key Words: Stem Cells, Biotechnology, Parthenogenesis

International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com
or
Brian Lundstrom, President
760-640-6383
bl@intlstemcell.com

The lurking fear in Tredinnick’s Integrated Health Care debate

Posted on by

Last week I mentioned that David Tredinnick, Conservative MP for Bosworth, was being a bit silly in the lead up to his adjournment debate on integrated healthcare.  At the time I boldly suggested that if Tredinnick was the best ally alternative health had in the Houses of Parliament then it was in a great deal of trouble.  Sadly I may have been too confident.  The transcript of the debate is now available and Tredinnick’s contributions are as fanciful as you would expect.  However, it is not these that cause me concern, the man is not a credible figure and his voice carries little wait in tilting the healthcare debate one way or another, it is Anne Milton, the Under Secretary of State for Public Health, whose replies are troubling in many respects.  Readers may be interested in her pronouncements about ‘service providers’, and changes to the structure of NHS healthcare, which suggest some hard questions about their commitment public healthcare need to be asked of the new government.  My focus though, as usual, will be on those replies more pertinent to quackery and its regulation.  While Milton is clear and sensible on the need to defer to NICE and the evidence base, especially in these uncertain economic times where finite NHS resources are already strained and further threatened by the enthusiastic swishing scalpels in the Treasury, there are nevertheless some arguments that offer succour to alternative practitioners.

From her second paragraph:

My hon. Friend may be interested to know that although I trained as a nurse and worked in the NHS for 25 years in conventional medicine, my grandmother trained at the homeopathic hospital in London, and was herself a homeopathic nurse. Later, she became a Christian Scientist. I am therefore not without my own roots in alternative therapies. My hon. Friend may also be interested to know that my grandmother never, until her death at the age of 89, took any conventional medicine.

While this may be an opening gambit of flattery, designed to lessen the rejection of Tredinnick’s ideas, the claim about her grandmother does not seem particularly appropriate.  While good health, of the sort that lets you live until 89, may not require conventional medicine so much as luck, in both genes and environment, it is undeniable that many lives are saved by its use.  To imply by anecdote, not the most reliable of measures, that homeopathy may allow one to live long in the absence of accepted healthcare is unbecoming of a health minister upon whose decisions the health of millions rests. Worryingly the following paragraph suggests the the Minister may indeed have some mistaken opinions about the benefits of an agitated sugar pill.

My hon. Friend raised the issue of homeopathic hospitals and his concern about them. I understand that there are five such hospitals in the United Kingdom, based in London, Bristol, Tunbridge Wells, Liverpool and Glasgow. However, the Tunbridge Wells homeopathic hospital stopped providing services in March 2009 owing to the primary care trust’s decision to end funding. All the hospitals have experienced a reduction in the number of referrals over the past three years, and it has been claimed that all of them are now in a precarious position as a result of such significant funding losses. That is a matter of concern, given that they have clearly offered valuable treatments to patients.

I would like to know the evidence that showed clear benefit from these relics.  It certainly isn’t in the Science and Technology Committee report on homeopathy, which the Minister claims to be considering:

I note my hon. Friend’s comments on the Lords [sic] Science and Technology Committee report on homeopathy, and I am aware that it caused quite a lot of concern. It was published on 22 February, and we are still considering it and will formally respond in due course. He raised considerable concerns about the report, and highlighted the low cost of many alternative therapies and the important contributions they make. He also made reference to experiences from around the world-he mentioned Australia in particular, and also the USA-and he made an important point about the open-mindedness of some countries to alternative therapies.

In considering outcomes, patient-reported outcome measures must be an important factor. As my hon. Friend rightly said-and as I mentioned-individuals’ own experiences are very important, and if we want to achieve the best outcomes, one step we must take is to ask the patient whether they actually got better.

In conclusion, I wish to thank my hon. Friend for his contribution to the debate and to suggest that perhaps the picture is not as bleak as he fears-I noted a certain weariness in his voice; he feels that he has raised this issue on so many occasions and it has fallen on deaf ears.

I do not expect the government to fundamentally disagree with the reports recommendations, that would be a foolish fight to choose given homeopathy’s many vociferous critics, however the comment about patient-reported outcome measures intrigues.  As mentioned in the previous post on Tredinnick, these are the brain child of Boo Armstrong, ex-writer for an AIDS denialist magazine and former Chief Executive of the Prince’s Foundation for Integrated Health (FIH), and a rather curious thing for the Minister to pick up on.  While an inherently weak form of evidence that NICE would not normally consider, they are amenable to misinterpretation by those seeking to attribute what most would consider human bias to unscientific modalities, or magic if you prefer.  One wonders who briefed Anne Milton before this debate and why she considers that alternative therapies are not as threatened as Tredinnick fears?

Perhaps the answer to this lies in the new government’s views on regulation:

The issue of regulation was raised, and it is a thorny one. When I was a shadow Health Minister, I met on numerous occasions psychologists, psychotherapists and counsellors who were very concerned about the regulation of their professions. Across the professions allied to health care, there are those who are keen on regulation and those who feel regulation would be wrong and would be unable to deal with the intricacies of their work. There is no doubt that vulnerable people are often preyed upon by unskilled and unscrupulous practitioners, and I think that professions wanting to achieve the highest standards will welcome proper regulation. The issue for Government is always whether statutory regulation is the most appropriate way of dealing with that risk, or if a lighter-touch approach would be more appropriate. That is why, as I understand it, last year the Department of Health, along with devolved Departments, consulted on the regulation of practitioners of acupuncture, herbal medicine and traditional Chinese medicine. As my hon. Friend will be aware, the consultation closed in November, and more than 6,000 responses were received. The high response rate is a testament to the strength of feeling about public access to complementary and alternative medicines; I am sure I am not alone in having received a huge number of letters on the subject.

The consultation examined in detail the options for regulation, including alternatives to statutory regulation. Once the Government have considered the consultation responses, we will make clear the next steps in the regulatory process. In acknowledgment of my hon. Friend’s keen interest in the matter, I am very happy to keep in touch with him about it. In the meantime, the Complementary and Natural Healthcare Council [CNHC] provides for voluntary registration for practitioners from nine complementary therapy disciplines. I appreciate that my hon. Friend feels that that is not sufficient, but that is in place for the moment while we consider the consultation that has taken place and make a decision on what the next steps should be.

While there is no firm commitment to any particular position here there are two things the Minister needs to consider.

1) ‘light touch’ regulation does not work.

The CNHC have declared that they will ignore complaints from some members of the public, and have been utterly ineffectual in what little concerns they have considered. Not only that they have had to tolerate some outrageous conspiracy theories and false accusations widely circulated by email.

2) Statutory regulation does not work.

Consider the Chiropractors, The General Chiropractic Council (GCC) are supposed to be the statutory body that regulates Chiropractic.  However, since one of the GCC affiliate associations decided to unsuccessfully sue Simon Singh, the profession has found itself under considerable scrutiny, with many of its members subjected to professional standards complaints.  The GCC have been obstructive, inconsistent, dishonest and completely ineffectual in dealing with these.

The regulation of quackery requires some fresh thinking and if the government chooses either of the options above then there will only be chaos from quacks and complaints from skeptics.  Whatever their choice it looks like the eternal battle between reason and woo will continue.  With the collapse of the FIH, quackery is in search of new allies and its former employees may already be making contacts.  As the governments ideologically enthusiastic and economically necessary cuts bite, the temptation to favour cheap placebos may lead many astray.  Anne Milton may not yet have chosen her side, but her lack of commitment is telling, the dark mutterings of the deluded are being listened to if not yet obeyed.

Lifeblood

Posted on by

John Ross Lifeblood

John Ross Lifeblood

John Ross Lifeblood

Whoa now, these images are AWESOME! They were created by the design studio FARROW for the CD art of The Maniac Street Preachers album, Lifeblood, photography by John Ross. The images are totally stunning and, as mentioned on the Farrow site, were created by pouring buckets of fake blood all over a very dashing model, who was later taken out of the images in post production. That must have been an awesome/messy/fun photo shoot set! Be sure to check out both the Design firm and the photographers site for more images!

[via todayandtomorrow]